Also: Eli Lilly will start providing low-dose vials of its obesity drug Zepbound through its direct-to-consumer platform

August 27, 2024 Check out STAT+

Sponsored By

Hey — for a special STAT+ discount, use the code LABORDAY to get 25% your first year of our premium membership. Don't miss out.

Gerald Herbert/AP 21 cases of little-known Oropouche virus detected in U.S. The individuals all contracted the insect-borne virus, sometimes referred to as "sloth fever" during travel this summer to Cuba. By Helen Branswell STAT+ | Lilly launches Zepbound vials in move that could ease supply constraints Dosages of Zepbound pens go up to 10 and 15 mg, but Lilly is only offering low-doses vials for now. By Elaine Chen STAT+ | To help migraine patients — and sell more medicines — major drugmakers turn to telehealth Migraine drugs will be a focus of new online portal as Pfizer joins Eli Lilly and other pharmaceutical companies in turning to direct-to-consumer websites. By Katie Palmer Adobe STAT+ | Centene eliminates brokers' commissions for Medicare drug plans The decision by the largest Medicare Part D carrier may end up steering policyholders toward Medicare Advantage plans. By Bob Herman STAT+ | Pharmalittle: We're reading about Lilly cutting Zepbound's price; Pfizer selling direct to consumers, and more The European Commission authorized a Regeneron Pharmaceuticals medication, Ordspono, to treat two types of lymphoma By Ed Silverman Opinion: To stop mpox from becoming the next pandemic, we must address global vaccine inequities A doctor who treated mpox patients in 2022 explains how global vaccine inequities are making it harder to tackle the new outbreak. By Wilfredo R. Matias

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser